why choose us

First received: June 12, 2024

Clinical Trial: MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Metabolic- Associated Fatty Liver Disease (MAFLD)

Study Type: OBSERVATIONAL


Official Title: The Accuracy of MAFLD Fibrosis Score in Detecting Fibrotic NASH in MAFLD Egyptian Patients

Brief Summary: Metabolic-associated fatty liver disease (MAFLD), is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty infiltration.The incidence of MAFLD is increasing yearly, and its incidence rate is as high as 20% to 30% on a global scale, which seriously affects people's health.Non-alcoholic steatohepatitis (NASH), a chronic hepatitis that can progress to advanced fibrosis, decompensated cirrhosis, and hepatocellular carcinoma, affects one-fifth of NAFLD patients.Depending…

Read more